Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Brief Summary: This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.


Options:
A: Arm Label: TMC435 25 mg (Cohort 1/Panel A and B); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 75mg (Cohort 1/Panel A and B); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: Placebo (Cohort 1/Panel A and B); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 200 mg (Cohort 2, Panel A and B); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: Placebo (Cohort 2/Panel A and B); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 75 mg (Cohort 4/Panel C); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 150 mg (Cohort 4/Panel C); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 200 mg (Cohort 4/Panel C); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: Placebo (Cohort 4/Panel C); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Arm Label: TMC435 200 mg (Cohort 5/Panel D); Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon (PegIFNα-2a), Drug: Ribavirin | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 150 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 2, Panel A and B), TMC435 200 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 5/Panel D), TMC435 25 mg (Cohort 1/Panel A and B), TMC435 75 mg (Cohort 4/Panel C), TMC435 75mg (Cohort 1/Panel A and B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Cohort 1/Panel A and B), Placebo (Cohort 2/Panel A and B), Placebo (Cohort 4/Panel C) | Intervention Type: DRUG; Name: Peginterferon (PegIFNα-2a); Assigned to Arm(s): Placebo (Cohort 1/Panel A and B), Placebo (Cohort 2/Panel A and B), Placebo (Cohort 4/Panel C), TMC435 150 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 2, Panel A and B), TMC435 200 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 5/Panel D), TMC435 25 mg (Cohort 1/Panel A and B), TMC435 75 mg (Cohort 4/Panel C), TMC435 75mg (Cohort 1/Panel A and B) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo (Cohort 1/Panel A and B), Placebo (Cohort 2/Panel A and B), Placebo (Cohort 4/Panel C), TMC435 150 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 2, Panel A and B), TMC435 200 mg (Cohort 4/Panel C), TMC435 200 mg (Cohort 5/Panel D), TMC435 25 mg (Cohort 1/Panel A and B), TMC435 75 mg (Cohort 4/Panel C), TMC435 75mg (Cohort 1/Panel A and B)
B: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
C: Arm Label: Genotype 2 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 2/3 treatment-experienced; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 1/3/4 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced
D: Arm Label: Group A: T12/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group B: T12(DS)/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group C: Pbo/PR48; Type: EXPERIMENTAL; Interventions: Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48

Answer: C